To the Editor: Ondansetron is a 5-HT3 receptor antagonist and an effective antiemetic in the treatment of acute chemotherapy- or radiotherapy-induced nausea and vomiting1 and postoperative nausea and vomiting.2 However, there is no evidence to support the superiority of ondansetron in the empirical management of undifferentiated nausea and vomiting,1 although this appears to have become common practice. Trials comparing ondansetron and other antiemetics (such as metoclopramide or promethazine) in the management of undifferentiated nausea have failed to show a significant difference in efficacy.3,4 Clinical guidelines for managing nausea and vomiting have been shown to increase compliance with consensus guidelines and reduce costs to health services associated with antiemetic prescribing.5
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
We would like to acknowledge the support of Ballarat Health Services in completing this audit, including the health information services staff for assistance in data extraction, and Kate Hamilton, Director of Oncology, for her guidance and support.
No relevant disclosures.